New FDA compounding restrictions - GLP’s skyrocket

In this episode of Pep-Talk, Max Plasencia and Mike Sheffer break down the latest FDA update and what it means for GLP-1 peptides like semaglutide and tirzepatide.With new restrictions on compounding pharmacies, prices are expected to rise significantly - and access could become more limited.💡 What You’ll Learn:What the new FDA compounding restrictions actually meanWhy GLP-1 prices are about to skyrocketHow this impacts semaglutide & tirzepatide usersCompounding pharmacy vs pharmaceutical productsResearch peptides vs prescribed peptides explainedRisks, quality differences & what to watch out forHow to make smarter decisions in this changing market⏱️ CHAPTERS:00:00 Intro01:00 New FDA Compounding Restrictions03:30 Why GLP Prices Will Skyrocket07:00 Semaglutide & Tirzepatide Explained12:00 Compounding Pharmacies vs Big Pharma18:00 Supply vs Demand Breakdown24:00 Research Peptides vs Prescriptions30:00 Quality & Safety Differences36:00 The Truth About Doctors & Clinics44:00 Cerebrolysin Update52:00 Epitalon & Longevity58:00 Final ThoughtsBuy Peptides online at Prime Longevity Peptides: Enter code:welcome20 for 20% off your first order:⁠⁠https://primelongevitypeptides.com⁠⁠Join Our Community Group: GLP& Peptide Warriors: Science-Backed & SupportedInstagram @mikesheffer_Instagram ⁠prime_longevity_protocol⁠Email - [email protected]